Representative clinical trials initiated within mainland China
| Trial identifier number | Study title | Interventions | Duration | Participants | Primary end-points | Recruitment status |
| NCT04601792 | A Series of N-of-1 Trials of Traditional Chinese Medicine Based on Bayesian Method | Drug: Individualised Decoction Drug: placebo Drug: Tested drug minus heat-clearing herbs | 4 weeks per period ×3 | 71 | Patient Self-Rated Symptom Score (Likert scale) | Recruiting |
| NCT03715322 | Tobramycin in Bronchiectasis Colonised With Pseudomonas aeruginosa (TORNASOL) | Drug: Tobramycin Inhalant Product Other: usual care Drug: Natural saline inhalation | 4 months | 350 | Changes in sputum load of Pseudomonas aeruginosa at day 29 compared with baseline; Changes in Quality of Life in Bronchiectasis-Respiratory Symptom Score at day 29 compared with baseline | Completed |
| NCT02088216 | Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectasis (BENE) | Drug: N-acetylcysteine Other: On-demand treatment | 12 months | 161 | Median Number of Exacerbations over 12 months | Completed |
| NCT03843541 | A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions | Drug: N-acetylcysteine (NAC) 600 mg Drug: Ambroxol hydrochloride 30 mg Other: placebo | 4 weeks | 333 | Change from baseline to end of 1-week treatment of mean sputum viscosity score of NAC and placebo; Change from baseline to end of 1-week treatment of mean expectoration difficulty score of NAC and placebo | Completed |